HealthTree Foundation

New research from #ASH25 shows how AI tools and genetic testing may improve how lymphoma is classified and understood. These advances could help doctors identify lymphoma subtypes more accurately and better understand relapse patterns in diseases like DLBCL. Learn more: 👉 healthtree.org/lymphoma/commu… #Lymphoma #DLBCL #CancerResearch #PrecisionMedicine #HealthTree

A new global study explored adding tafasitamab to lenalidomide + rituximab for relapsed or refractory follicular lymphoma. The results showed a meaningful improvement in how long patients lived without disease progression. Learn what this could mean for future treatment options. 👉 healthtree.org/follicular-lym… #FollicularLymphoma #LymphomaResearch #BloodCancer #CancerResearch #HealthTree

Join the conversation on MRD in multiple myeloma. 🩸 The 13th Annual Miami Myeloma MRD Meeting 2026 brings together leading experts, including @DrOlaLandgren , to discuss the latest research on Minimal Residual Disease. 🗓️ April 10, 2026 📍 Miami, FL | Virtual access healthtree.org/myeloma/commun… #MultipleMyeloma

New research explores how salvage therapy may help some people with AML achieve remission. Learn more: 🔗healthtree.org/aml/community/… #AML #BloodCancer #HealthTree

Innovations in #MultipleMyeloma have nearly doubled life expectancy for some. We’re proud to deliver breakthrough therapies and grateful for the power of community organizations like @HealthTree. Together, we're building a stronger community 🤝 🔍 healthtree.org

Gayaythri Ravi, MD shares the eye care management of patients using the BCMA directed antibody drug conjugate Blenrep. #mmsm HealthTree Nashville Roundtable.

Car T cell therapy provides durable responses in myeloma and can now be used in earlier therapy in myeloma. Mark Schroeder, MD at the HewlthTree Nashville Roundtable. #mmsm Age is not a factor in getting CAR T

We need better testing in newly diagnosed myeloma with next generation sequencing instead of FISH testing. Muhamed Baljevic, MD at the HealthTree Nashville Roundtable #mmsm ⁦@MMBaljevicMD⁩

Hans Lee, MD sharing the brand new FDA approval of teclistamab and daratumumab that happened last weekend for myeloma patients at the HealthTree Nashville Roundtable. #mmsm

Hans Lee, MD describes the impressive response rates of bispecific antibodies in #myeloma at the Nashville HealthTree Roundtable. #mmsm

jnj.com/media-center/p… @JNJNews

🚨 FDA Approval: The U.S. FDA approved teclistamab (Tecvayli) + daratumumab (Darzalex Faspro) for adults with relapsed/refractory multiple myeloma after at least one prior therapy. Results from the phase 3 MajesTEC-3 trial showed improved outcomes vs. standard therapies. Read more: healthtree.org/myeloma/commun… #mmsm

Looking forward to hear Dr. Krisstina Gowin (@kgowinDO) discuss how patients with multiple #myeloma can harness the power of integrative oncology on March 11, 2026. More info @HealthTree healthtree.org/myeloma/commun…

Big news!! #mmsm Tec-Dara gets FDA approval. fda.gov/news-events/pr… @IMFmyeloma @theMMRF @HealthTree

💜 March is Multiple Myeloma Awareness Month. HealthTree is highlighting innovation in research that’s improving diagnosis, treatment, and outcomes for patients. This month, patients can connect medical records, explore treatment options, and join the HealthTree community. Sharing these resources helps patients access tools and opportunities that accelerate progress. htree.org/myelomaawarene… Thank you to our Myeloma Awareness Month sponsors: @pfizer , @gileadsciences, @KitePharma , and @arcellx, for their continued support. #MyelomaAwarenessMonth #InnovationInMyeloma #PatientPoweredResearch